CD4+ T-Cell Recognition of Mutated B-RAF in Melanoma Patients Harboring the V599E Mutation

Melinda S. Sharkey, Gregory Lizée, Monica I. Gonzales, Sima Patel, Suzanne Topalian

Research output: Contribution to journalArticle

Abstract

The potential of antigen-directed cancer immunotherapy has not been fully realized, perhaps because many commonly targeted tumor associated proteins are not essential to maintaining the malignant cell phenotype. A constitutively activating mutation in the signaling molecule BRAF is expressed frequently in melanomas and may play an important role in the biology of this disease. A 29-mer B-Raf peptide incorporating the V599E mutation was used for in vitro stimulation of lymphocytes derived from melanoma patients, generating MHC class II-restricted CD4+ T cells specific for this peptide as well as for melanoma cells expressing B-Raf V599E. Mutated B-Raf exemplifies targets that may be ideal for immunotherapy.

Original languageEnglish (US)
Pages (from-to)1595-1599
Number of pages5
JournalCancer Research
Volume64
Issue number5
DOIs
StatePublished - Mar 1 2004
Externally publishedYes

Fingerprint

Melanoma
T-Lymphocytes
Immunotherapy
Mutation
Lymphocyte Activation
Neoplasms
Phenotype
Antigens
Peptides
Proteins
In Vitro Techniques
peptide B

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

CD4+ T-Cell Recognition of Mutated B-RAF in Melanoma Patients Harboring the V599E Mutation. / Sharkey, Melinda S.; Lizée, Gregory; Gonzales, Monica I.; Patel, Sima; Topalian, Suzanne.

In: Cancer Research, Vol. 64, No. 5, 01.03.2004, p. 1595-1599.

Research output: Contribution to journalArticle

Sharkey, Melinda S. ; Lizée, Gregory ; Gonzales, Monica I. ; Patel, Sima ; Topalian, Suzanne. / CD4+ T-Cell Recognition of Mutated B-RAF in Melanoma Patients Harboring the V599E Mutation. In: Cancer Research. 2004 ; Vol. 64, No. 5. pp. 1595-1599.
@article{1c0e960e5f164158a7c0c23d93cdcce7,
title = "CD4+ T-Cell Recognition of Mutated B-RAF in Melanoma Patients Harboring the V599E Mutation",
abstract = "The potential of antigen-directed cancer immunotherapy has not been fully realized, perhaps because many commonly targeted tumor associated proteins are not essential to maintaining the malignant cell phenotype. A constitutively activating mutation in the signaling molecule BRAF is expressed frequently in melanomas and may play an important role in the biology of this disease. A 29-mer B-Raf peptide incorporating the V599E mutation was used for in vitro stimulation of lymphocytes derived from melanoma patients, generating MHC class II-restricted CD4+ T cells specific for this peptide as well as for melanoma cells expressing B-Raf V599E. Mutated B-Raf exemplifies targets that may be ideal for immunotherapy.",
author = "Sharkey, {Melinda S.} and Gregory Liz{\'e}e and Gonzales, {Monica I.} and Sima Patel and Suzanne Topalian",
year = "2004",
month = "3",
day = "1",
doi = "10.1158/0008-5472.CAN-03-3231",
language = "English (US)",
volume = "64",
pages = "1595--1599",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - CD4+ T-Cell Recognition of Mutated B-RAF in Melanoma Patients Harboring the V599E Mutation

AU - Sharkey, Melinda S.

AU - Lizée, Gregory

AU - Gonzales, Monica I.

AU - Patel, Sima

AU - Topalian, Suzanne

PY - 2004/3/1

Y1 - 2004/3/1

N2 - The potential of antigen-directed cancer immunotherapy has not been fully realized, perhaps because many commonly targeted tumor associated proteins are not essential to maintaining the malignant cell phenotype. A constitutively activating mutation in the signaling molecule BRAF is expressed frequently in melanomas and may play an important role in the biology of this disease. A 29-mer B-Raf peptide incorporating the V599E mutation was used for in vitro stimulation of lymphocytes derived from melanoma patients, generating MHC class II-restricted CD4+ T cells specific for this peptide as well as for melanoma cells expressing B-Raf V599E. Mutated B-Raf exemplifies targets that may be ideal for immunotherapy.

AB - The potential of antigen-directed cancer immunotherapy has not been fully realized, perhaps because many commonly targeted tumor associated proteins are not essential to maintaining the malignant cell phenotype. A constitutively activating mutation in the signaling molecule BRAF is expressed frequently in melanomas and may play an important role in the biology of this disease. A 29-mer B-Raf peptide incorporating the V599E mutation was used for in vitro stimulation of lymphocytes derived from melanoma patients, generating MHC class II-restricted CD4+ T cells specific for this peptide as well as for melanoma cells expressing B-Raf V599E. Mutated B-Raf exemplifies targets that may be ideal for immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=1642363984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642363984&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-03-3231

DO - 10.1158/0008-5472.CAN-03-3231

M3 - Article

C2 - 14996715

AN - SCOPUS:1642363984

VL - 64

SP - 1595

EP - 1599

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 5

ER -